# Interleukin-23 Monoclonal Antibody for Inflammatory Bowel Disease: Efficacy and Safety

> **NCT07216014** · PHASE4 · RECRUITING · sponsor: **Sixth Affiliated Hospital, Sun Yat-sen University** · enrollment: 200 (estimated)

## Conditions studied

- Crohn's Disease and Ulcerative Colitis

## Interventions

- **DRUG:** Interleukin 23
- **DEVICE:** Interleukin 23

## Key facts

- **NCT ID:** NCT07216014
- **Lead sponsor:** Sixth Affiliated Hospital, Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-01
- **Primary completion:** 2026-09-30
- **Final completion:** 2026-10-10
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07216014

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07216014, "Interleukin-23 Monoclonal Antibody for Inflammatory Bowel Disease: Efficacy and Safety". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07216014. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*